These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 15366967

  • 1. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ, Iglesias E, Aguilar JC, Cabrales A, Reyes O, Andreu D.
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [Abstract] [Full Text] [Related]

  • 2. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 3. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL, Schad VC, Goodwin WH, Brauer AB, Bollinger BK, Chin RD, Kuo MC.
    J Immunol; 1992 Jun 15; 148(12):3970-7. PubMed ID: 1376346
    [Abstract] [Full Text] [Related]

  • 4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 15; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 5. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J, Boutillon C, Georges B, Ameisen JC, Tartar A, Auriault C.
    J Pept Sci; 1996 Mar 15; 2(3):165-75. PubMed ID: 9231325
    [Abstract] [Full Text] [Related]

  • 6. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Mar 15; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 7. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
    Cruz LJ, Quintana D, Iglesias E, Garcia Y, Huerta V, Garay HE, Duarte C, Reyes O.
    J Pept Sci; 2000 May 15; 6(5):217-24. PubMed ID: 10823490
    [Abstract] [Full Text] [Related]

  • 9. A comparative study of different presentation strategies for an HIV peptide immunogen.
    Cruz LJ, Iglesias E, Aguilar JC, González LJ, Reyes O, Albericio F, Andreu D.
    Bioconjug Chem; 2004 May 15; 15(1):112-20. PubMed ID: 14733590
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B, Manor R, Mor A, Arshava B, Rosen O, Ding FX, Naider F, Anglister J.
    Biochemistry; 2009 Aug 25; 48(33):7867-77. PubMed ID: 19552398
    [Abstract] [Full Text] [Related]

  • 13. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A, Hamajima K, Nakajima K, Kawamoto S, Phanuphak P.
    J Mol Recognit; 1993 Sep 25; 6(3):101-9. PubMed ID: 8060667
    [Abstract] [Full Text] [Related]

  • 14. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Vu HM, de Lorimier R, Moody MA, Haynes BF, Spicer LD.
    Biochemistry; 1996 Apr 23; 35(16):5158-65. PubMed ID: 8611499
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C, Pedroza-Roldan C, Viveros M, Gevorkian G, Manoutcharian K.
    Vaccine; 2011 Jul 18; 29(32):5313-21. PubMed ID: 21600948
    [Abstract] [Full Text] [Related]

  • 18. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K, Sällberg M, Sönnerborg A.
    AIDS Res Hum Retroviruses; 1994 Nov 18; 10(11):1551-6. PubMed ID: 7534097
    [Abstract] [Full Text] [Related]

  • 19. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T, Kurth R, Norley S.
    J Immunol; 1994 Aug 15; 153(4):1895-904. PubMed ID: 7519220
    [Abstract] [Full Text] [Related]

  • 20. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1.
    Casement KS, Nehete PN, Arlinghaus RB, Sastry KJ.
    Virology; 1995 Aug 01; 211(1):261-7. PubMed ID: 7645219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.